WB, IP
H
Endogenous
75
Rabbit IgG
#P78415
79191
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:50 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human
Species predicted to react based on 100% sequence homology
The antigen sequence used to produce this antibody shares
100% sequence homology with the species listed here, but
reactivity has not been tested or confirmed to work by CST.
Use of this product with these species is not covered under
our
Product Performance Guarantee.
Mouse, Rat, Bovine
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro485 of human IRX3 protein.
Background
The Iroquois-class homeodomain proteins (IRX1-6) comprise a family of transcription factors, initially identified in a mutagenesis experiment in Drosophila designed to identify genes involved in embryonic patterning (1,2). Members of the Iroquois-class protein family contain a three amino acid loop extension (TALE) homeodomain and an IRO sequence motif of unknown function that is unique to this protein family, but which bears similarity to Notch receptor domains involved in protein-protein interactions (3,4). Research studies in various animal models suggest important roles for IRX proteins in early development, including neural patterning, heart field specification, kidney development, and lung development (5-8). Moreover, studies in mice have shown an essential role for IRX proteins in eye development, where they are required for the specification of ommatidia and photoreceptor cells (9).
IRX3 is expressed during nervous system, renal, and cardiac development and controls genetic programs that guide development of these organs (10). Research studies have demonstrated that mice lacking both Irx3 and its paralog, Irx5, die in utero due, in part, to cardiac defects (11). In the context of human disease, research studies have demonstrated that IRX3 is aberrantly overexpressed and oncogenic in multiple types of human hematologic malignancies, including acute myeloid leukemia (AML) (12,13).
- Dambly-Chaudière, C. and Leyns, L. (1992) Int J Dev Biol 36, 85-91.
- Leyns, L. et al. (1996) Mech Dev 59, 63-72.
- Cavodeassi, F. et al. (2001) Development 128, 2847-55.
- Lai, E.C. et al. (1998) Development 125, 4077-88.
- Bosse, A. et al. (1997) Mech Dev 69, 169-81.
- Christoffels, V.M. et al. (2000) Dev Biol 224, 263-74.
- Marra, A.N. and Wingert, R.A. (2014) Cell Dev Biol 3, 1000131.
- Becker, M.B. et al. (2001) Mech Dev 106, 155-8.
- Choy, S.W. et al. (2010) Dev Dyn 239, 3204-14.
- Houweling, A.C. et al. (2001) Mech Dev 107, 169-74.
- Gaborit, N. et al. (2012) Development 139, 4007-19.
- Somerville, T.D.D. et al. (2018) Cell Rep 22, 638-652.
- Camera, F. et al. (2023) iScience 26, 107319.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting IP: Immunoprecipitation
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.